Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit or (NCT03062540).

Stock Info
: Analyst Coverage

Analyst Coverage

Firm Analyst
Brookline Capital Markets Kumaraguru Raja
Roth Capital Partners Scott R. Henry, CFA
Dawson James Bob Wasserman
Zacks Investment Research, Inc. David Bautz, PhD


Tonix Pharmaceuticals Holding Corp. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Tonix Pharmaceuticals Holding Corp.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tonix Pharmaceuticals Holding Corp. or its management. Tonix Pharmaceuticals Holding Corp. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.